EndoTex Interventional Systems Inc.
This article was originally published in Start Up
EndoTex has chosen to focus on two of the largest non-coronary applications among vascular disorders, AAAs and carotid artery disease.
You may also be interested in...
In Vivo interviews device entrepreneur Fred Khosravi about his secrets for success in medical device company creation. Khosravi was part of the ACS organization that eventually became Guidant, where he was on the leading edge of the coronary stent revolution. That experience provided Khosravi with a broad background in interventional cardiology devices that was useful in starting his first company, carotid stent company EndoTex Interventional Systems (which was acquired by Boston Scientific) and several other successful companies.
The first generation less-invasive devices for abdominal aortic aneurysm (AAA) surgery haven't yet been approved and the next generation is already here.
The addition of the question “Was this device serviced by a third party servicer?” to adverse event reports filed through the US FDA’s electronic Medical Device Reporting system could prove helpful for the agency and device makers, experts tell Medtech Insight. Industry has long complained about poor work performed by servicers – and loudly groused that they’re not regulated.